GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citi Pharma Ltd (KAR:CPHL) » Definitions » Buildings And Improvements

Citi Pharma (KAR:CPHL) Buildings And Improvements : ₨0.00 Mil (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is Citi Pharma Buildings And Improvements?


Citi Pharma Buildings And Improvements Historical Data

The historical data trend for Citi Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citi Pharma Buildings And Improvements Chart

Citi Pharma Annual Data
Trend
Buildings And Improvements

Citi Pharma Semi-Annual Data
Buildings And Improvements

Citi Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Citi Pharma Business Description

Traded in Other Exchanges
N/A
Address
588 Q Block, Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its departments include Active Pharma Ingredients (API) and Formulations. Some of its products include Askprol C Tab, Lenon Tab, Recoz Tab, Cingol Tab among others.

Citi Pharma Headlines

No Headlines